Drug Profile
CIGB 55
Alternative Names: Anti-IL-15 peptide - CIGBLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
- Class
- Mechanism of Action Immunosuppressants; Interleukin 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in Cuba
- 25 Feb 2016 CIGB has patent protection for CIGB 55 in USA, the EU, Japan, Australia, Canada, China, Russia, Mexico and South Africa prior to February 2016
- 01 Dec 2014 CIBG 55 is available for licensing as of 01 Dec 2014.